RGNX

8.89 USD

+2.95%

Today

-1.58%

Market is closed

Sun

Closed

Mon

4:30 PM ~ 11:00 PM

Tue

4:30 PM ~ 11:00 PM

Wed

4:30 PM ~ 11:00 PM

Thu

4:30 PM ~ 11:00 PM

Fri

4:30 PM ~ 11:00 PM

Sat

Closed

Loading chart...

MAX

Information

Name

Regenxbio Leveraged

Currency

USD

Standard Leverage

Enhanced Leverage

Overnight Fees Buy

-0.0191%

Overnight Fees Sell

0.0024%

Market Cap

447.48M

Avg Daily Volume

634.66K

52 Week High

16.19 USD

52 Week Low

5.035 USD

Trading Hours

See hours

Overnight Fees Calculator

Trade Size

ExposureUnits

USD

	Daily Overnight Fee %	Daily Overnight Fee $
BUYS	-0.01910%	$(0.191)
SELLS	0.00240%	$0.024

*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.

Business Summary

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.